NASDAQ:KURA - Kura Oncology Stock Price, Price Target & More

$16.80 -0.65 (-3.72 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$17.45
Today's Range$16.70 - $17.79
52-Week Range$5.90 - $24.02
Volume182,488 shs
Average Volume341,204 shs
Market Capitalization$597.03 million
P/E Ratio-11.02
Dividend YieldN/A
Beta4.21

About Kura Oncology (NASDAQ:KURA)

Kura Oncology logoKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Debt-to-Equity Ratio0.07%
Current Ratio9.44%
Quick Ratio9.44%

Price-To-Earnings

Trailing P/E Ratio-11.02
Forward P/E Ratio-11.75
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book6.36

Profitability

EPS (Most Recent Fiscal Year)($1.52)
Net Income$-35,430,000.00
Net MarginsN/A
Return on Equity-53.91%
Return on Assets-44.75%

Miscellaneous

Employees32
Outstanding Shares33,350,000

How to Become a New Pot Stock Millionaire

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How were Kura Oncology's earnings last quarter?

Kura Oncology (NASDAQ:KURA) released its quarterly earnings data on Monday, March, 12th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.01. View Kura Oncology's Earnings History.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Kura Oncology.

What price target have analysts set for KURA?

6 brokerages have issued 1-year price targets for Kura Oncology's stock. Their predictions range from $18.00 to $28.00. On average, they anticipate Kura Oncology's share price to reach $22.00 in the next year. View Analyst Ratings for Kura Oncology.

What are Wall Street analysts saying about Kura Oncology stock?

Here are some recent quotes from research analysts about Kura Oncology stock:
  • 1. Cann analysts commented, "The KO-947 phase I program is on track for an on-time enrollment, with data expected in the second half of this year from the phase I study. Findings presented at AACR today could inform future clinical studies for KO-947, by targeting a subset of head and neck, and esophageal patients, based on a precision medicine model. We conclude that KO-947 continues to be a promising asset, based on preclinical data, but is not anticipated to have revenue impact to Kura Oncology by 2022; therefore, we are not making any adjustments to our estimates or outlook." (4/17/2018)
  • 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (3/22/2018)

Who are some of Kura Oncology's key competitors?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the folowing people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 49)
  • Ms. Annette North, Sr. VP & Gen. Counsel (Age 52)
  • Dr. Antonio Gualberto, Chief Medical Officer & Head of Devel. (Age 53)
  • Ms. Heidi Henson, CFO & Sec. (Age 52)
  • Dr. Yi Liu Ph.D., Chief Scientific Officer (Age 50)

Has Kura Oncology been receiving favorable news coverage?

Press coverage about KURA stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kura Oncology earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 44.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $16.80.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $597.03 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (KURA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kura Oncology (NASDAQ:KURA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Kura Oncology in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 30.95%. The high price target for KURA is $28.00 and the low price target for KURA is $18.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.00$22.60$18.30$15.75
Price Target Upside: 30.95% upside7.36% upside16.19% upside126.62% upside

Kura Oncology (NASDAQ:KURA) Consensus Price Target History

Price Target History for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018CannReiterated RatingBuy$27.00LowView Rating Details
2/16/2018CitigroupSet Price TargetBuy$28.00HighView Rating Details
12/26/2017WedbushInitiated CoverageBuy$19.00MediumView Rating Details
12/11/2017OppenheimerSet Price TargetBuy$18.00HighView Rating Details
9/7/2017CowenInitiated CoverageOutperformMediumView Rating Details
8/10/2017Leerink SwannReiterated RatingOutperform$16.00 -> $18.00HighView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Kura Oncology (NASDAQ:KURA) Earnings History and Estimates Chart

Earnings by Quarter for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.36)($0.30)($0.33)
Q2 20183($0.36)($0.31)($0.34)
Q3 20183($0.38)($0.35)($0.37)
Q4 20183($0.43)($0.40)($0.41)

Kura Oncology (NASDAQ KURA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018($0.34)N/AView Earnings Details
3/12/2018Q4 2017($0.36)($0.37)ViewListenView Earnings Details
11/7/2017Q3 2017($0.37)($0.38)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.43)($0.40)ViewListenView Earnings Details
5/15/2017Q1 2017($0.44)($0.39)ViewN/AView Earnings Details
3/14/2017Q4 2016($0.41)($0.38)ViewN/AView Earnings Details
11/7/2016Q3($0.41)($0.37)ViewListenView Earnings Details
8/10/2016Q2($0.34)($0.36)ViewListenView Earnings Details
5/11/2016Q1($0.35)($0.36)ViewN/AView Earnings Details
3/17/2016Q4($0.44)($0.42)ViewListenView Earnings Details
11/13/2015Q3 2015($0.42)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kura Oncology (NASDAQ:KURA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kura Oncology (NASDAQ KURA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.80%
Institutional Ownership Percentage: 58.56%
Insider Trading History for Kura Oncology (NASDAQ:KURA)
Insider Trading History for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ KURA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Kura Oncology (NASDAQ KURA) News Headlines

Source:
DateHeadline
Kura Oncology (KURA) Rating Lowered to Hold at Zacks Investment ResearchKura Oncology (KURA) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:49 PM
Kura Oncology (KURA) Stock Rating Reaffirmed by CannKura Oncology (KURA) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - April 17 at 1:27 PM
Kura Oncology (KURA) Receives Average Recommendation of "Buy" from AnalystsKura Oncology (KURA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 14 at 1:25 AM
Kura Oncology (KURA) Given "Outperform" Rating at Leerink SwannKura Oncology (KURA) Given "Outperform" Rating at Leerink Swann
www.americanbankingnews.com - April 11 at 5:35 PM
Kura Oncology (KURA) Cut to Hold at Zacks Investment ResearchKura Oncology (KURA) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 9 at 10:56 PM
Kura Oncology (KURA) Upgraded at Zacks Investment ResearchKura Oncology (KURA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 9 at 8:36 PM
Kura Oncology (KURA) Stock Rating Lowered by Zacks Investment ResearchKura Oncology (KURA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 9 at 11:02 AM
Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
feeds.benzinga.com - April 9 at 7:49 AM
 Brokerages Expect Kura Oncology (KURA) Will Post Earnings of -$0.33 Per Share Brokerages Expect Kura Oncology (KURA) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 8 at 1:22 PM
Kura Oncology (KURA) Upgraded by Zacks Investment Research to "Buy"Kura Oncology (KURA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 8 at 11:00 AM
Kura Oncology (KURA) Downgraded by Zacks Investment ResearchKura Oncology (KURA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 8:10 PM
Kura Oncology (KURA) Given Buy Rating at CannKura Oncology (KURA) Given Buy Rating at Cann
www.americanbankingnews.com - April 5 at 4:06 PM
ValuEngine Upgrades Kura Oncology (KURA) to HoldValuEngine Upgrades Kura Oncology (KURA) to Hold
www.americanbankingnews.com - April 3 at 1:20 PM
Kura Oncology (KURA) PT Raised to $19.00Kura Oncology (KURA) PT Raised to $19.00
www.americanbankingnews.com - March 31 at 8:16 PM
Kura Oncology (KURA) Stock Rating Lowered by BidaskClubKura Oncology (KURA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 30 at 2:19 PM
Kura Oncology (KURA) Cut to "Sell" at Zacks Investment ResearchKura Oncology (KURA) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:28 PM
What You Must Know About Kura Oncology Inc’s (NASDAQ:KURA) Market RisksWhat You Must Know About Kura Oncology Inc’s (NASDAQ:KURA) Market Risks
finance.yahoo.com - March 29 at 10:06 AM
Edited Transcript of KURA earnings conference call or presentation 7-Aug-17 8:30pm GMTEdited Transcript of KURA earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - March 28 at 4:15 PM
Edited Transcript of KURA earnings conference call or presentation 12-Mar-18 8:30pm GMTEdited Transcript of KURA earnings conference call or presentation 12-Mar-18 8:30pm GMT
finance.yahoo.com - March 27 at 10:09 AM
Kura Oncology (KURA) Lifted to "Buy" at Zacks Investment ResearchKura Oncology (KURA) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 11:52 PM
Zacks Investment Research Lowers Kura Oncology (KURA) to HoldZacks Investment Research Lowers Kura Oncology (KURA) to Hold
www.americanbankingnews.com - March 23 at 10:46 PM
Kura Oncology (KURA) Rating Lowered to Hold at BidaskClubKura Oncology (KURA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 23 at 7:56 PM
Kura Oncology Inc (KURA) Given Average Recommendation of "Buy" by BrokeragesKura Oncology Inc (KURA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 20 at 1:30 AM
Q1 2018 EPS Estimates for Kura Oncology Inc (KURA) Lowered by AnalystQ1 2018 EPS Estimates for Kura Oncology Inc (KURA) Lowered by Analyst
www.americanbankingnews.com - March 19 at 1:40 AM
Q1 2018 EPS Estimates for Kura Oncology Inc Cut by Wedbush (KURA)Q1 2018 EPS Estimates for Kura Oncology Inc Cut by Wedbush (KURA)
www.americanbankingnews.com - March 19 at 1:38 AM
Kura Oncology (KURA) Provides Regulatory Update on TipifarnibKura Oncology (KURA) Provides Regulatory Update on Tipifarnib
www.streetinsider.com - March 17 at 4:53 PM
BidaskClub Downgrades Kura Oncology (KURA) to BuyBidaskClub Downgrades Kura Oncology (KURA) to Buy
www.americanbankingnews.com - March 16 at 11:34 PM
FY2022 Earnings Estimate for Kura Oncology Inc Issued By Wedbush (KURA)FY2022 Earnings Estimate for Kura Oncology Inc Issued By Wedbush (KURA)
www.americanbankingnews.com - March 16 at 4:26 PM
Kura Oncology to Present at Oppenheimer 28th Annual Healthcare ConferenceKura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 16 at 10:00 AM
Brokers Set Expectations for Kura Oncology Incs Q1 2018 Earnings (KURA)Brokers Set Expectations for Kura Oncology Inc's Q1 2018 Earnings (KURA)
www.americanbankingnews.com - March 15 at 6:45 AM
FY2022 Earnings Estimate for Kura Oncology Inc (KURA) Issued By OppenheimerFY2022 Earnings Estimate for Kura Oncology Inc (KURA) Issued By Oppenheimer
www.americanbankingnews.com - March 14 at 4:24 PM
Kura Oncology Inc (KURA) Short Interest UpdateKura Oncology Inc (KURA) Short Interest Update
www.americanbankingnews.com - March 14 at 1:38 AM
Kura Oncology (KURA) Releases  Earnings Results, Misses Expectations By $0.01 EPSKura Oncology (KURA) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 13 at 7:14 AM
BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And CompanyBRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company
www.reuters.com - March 12 at 5:19 PM
Kura Oncology, Inc. to Host Earnings CallKura Oncology, Inc. to Host Earnings Call
finance.yahoo.com - March 12 at 5:19 PM
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial ResultsKura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 5:19 PM
Kura Oncology Inc (NASDAQ:KURA): Is Breakeven Near?Kura Oncology Inc (NASDAQ:KURA): Is Breakeven Near?
finance.yahoo.com - March 12 at 10:34 AM
Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial ResultsKura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 5 at 4:50 PM
Zacks: Brokerages Anticipate Kura Oncology Inc (KURA) Will Announce Earnings of -$0.34 Per ShareZacks: Brokerages Anticipate Kura Oncology Inc (KURA) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - March 5 at 12:10 PM
Kura Oncology (KURA) to Release Quarterly Earnings on MondayKura Oncology (KURA) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:34 AM
Kura Oncology (KURA) Upgraded at BidaskClubKura Oncology (KURA) Upgraded at BidaskClub
www.americanbankingnews.com - February 25 at 4:54 PM
Kura Oncology, Inc. (KURA) Given Average Rating of "Buy" by AnalystsKura Oncology, Inc. (KURA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 23 at 1:44 AM
Who Are The Major Shareholders Of Kura Oncology Inc (NASDAQ:KURA)?Who Are The Major Shareholders Of Kura Oncology Inc (NASDAQ:KURA)?
finance.yahoo.com - February 20 at 9:15 AM
Oppenheimer Comments on Kura Oncology, Inc.s FY2022 Earnings (KURA)Oppenheimer Comments on Kura Oncology, Inc.'s FY2022 Earnings (KURA)
www.americanbankingnews.com - February 19 at 9:18 AM
FY2022 Earnings Estimate for Kura Oncology, Inc. Issued By Wedbush (KURA)FY2022 Earnings Estimate for Kura Oncology, Inc. Issued By Wedbush (KURA)
www.americanbankingnews.com - February 19 at 9:18 AM
Kura Oncology, Inc. Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share (KURA)Kura Oncology, Inc. Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share (KURA)
www.americanbankingnews.com - February 19 at 2:18 AM
-$0.36 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter-$0.36 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter
www.americanbankingnews.com - February 16 at 5:12 PM
Brokers Issue Forecasts for Kura Oncology, Inc.s Q4 2018 Earnings (KURA)Brokers Issue Forecasts for Kura Oncology, Inc.'s Q4 2018 Earnings (KURA)
www.americanbankingnews.com - February 16 at 2:02 PM
Kura Oncology (KURA) Price Target Increased to $28.00 by Analysts at CitigroupKura Oncology (KURA) Price Target Increased to $28.00 by Analysts at Citigroup
www.americanbankingnews.com - February 16 at 11:24 AM
Kura Oncology (KURA) Upgraded by Zacks Investment Research to HoldKura Oncology (KURA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 8 at 12:09 PM

SEC Filings

Kura Oncology (NASDAQ:KURA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Kura Oncology (NASDAQ KURA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.